{"abstract": "The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.", "web_url": "https://www.nytimes.com/2012/08/07/business/alzheimers-drug-trials-halted.html", "snippet": "The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.", "lead_paragraph": "Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer\u2019s drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Trials for Alzheimer\u2019s Drug Halted After Poor Results", "kicker": null, "content_kicker": null, "print_headline": "Trials for Alzheimer\u2019s Drug Halted After Poor Results", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Clinical Trials", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 4, "major": "N"}, {"name": "subject", "value": "Alzheimer's Disease", "rank": 5, "major": "N"}], "pub_date": "2012-08-06T23:18:47+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Katie Thomas", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/eba6cc3e-ec90-54bc-a2cd-182b6931800f", "word_count": 299, "uri": "nyt://article/eba6cc3e-ec90-54bc-a2cd-182b6931800f"}